News headlines about Alkermes Plc (NASDAQ:ALKS) have trended somewhat positive this week, according to AlphaOne Sentiment Analysis. The research group, a subsidiary of Accern, identifies positive and negative news coverage by monitoring more than twenty million news and blog sources in real time. AlphaOne ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Alkermes Plc earned a media sentiment score of 0.12 on AlphaOne’s scale. AlphaOne also assigned press coverage about the company an impact score of 46 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the news stories that may have impacted AlphaOne’s scoring:
- Alkermes Plc (ALKS) Given a $70.00 Price Target at Credit Suisse Group AG (americanbankingnews.com)
- Alkermes Plc (ALKS) SVP Sells $572,300.00 in Stock (americanbankingnews.com)
- Alkermes Plc (ALKS) Director Richard F. Pops Sells 50,000 Shares (americanbankingnews.com)
- Varian Medical Systems, Inc. (NYSE:VAR) vs. Alkermes plc (NASDAQ:ALKS): Stocks Ratcheting Up Value – Geneva Journal (genevajournal.com)
- The Richard F. Pops Sells 25000 Shares of Alkermes Plc (ALKS) Stock – BangaloreWeekly (bangaloreweekly.com)
Several brokerages have recently commented on ALKS. Credit Suisse Group AG set a $70.00 target price on shares of Alkermes Plc and gave the company a “buy” rating in a report on Friday. Cowen and Company reiterated a “buy” rating on shares of Alkermes Plc in a report on Friday, April 28th. JPMorgan Chase & Co. set a $78.00 price objective on shares of Alkermes Plc and gave the stock a “buy” rating in a report on Thursday, April 27th. Morgan Stanley restated an “equal weight” rating and set a $62.00 price objective on shares of Alkermes Plc in a report on Monday, April 24th. Finally, Jefferies Group LLC restated a “buy” rating and set a $70.00 price objective on shares of Alkermes Plc in a report on Monday, April 3rd. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $63.55.
Alkermes Plc (NASDAQ:ALKS) last posted its quarterly earnings data on Thursday, April 27th. The company reported ($0.31) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.24) by $0.07. The business had revenue of $191.80 million during the quarter, compared to analysts’ expectations of $195.79 million. Alkermes Plc had a negative net margin of 36.92% and a negative return on equity of 12.75%. The firm’s quarterly revenue was up 22.3% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.16) earnings per share.
In related news, CMO Elliot Ehrich sold 11,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 15th. The stock was sold at an average price of $56.74, for a total transaction of $624,140.00. Following the completion of the sale, the chief marketing officer now directly owns 66,071 shares in the company, valued at $3,748,868.54. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Robert A. Breyer sold 4,000 shares of the business’s stock in a transaction that occurred on Thursday, March 2nd. The stock was sold at an average price of $60.00, for a total value of $240,000.00. Following the sale, the director now owns 7,156 shares of the company’s stock, valued at $429,360. The disclosure for this sale can be found here. Insiders have sold 199,800 shares of company stock valued at $11,638,101 over the last quarter. 4.75% of the stock is owned by company insiders.
About Alkermes Plc
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Receive News & Ratings for Alkermes Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes Plc and related companies with MarketBeat.com's FREE daily email newsletter.